vascular cognitive impairment
Conditions
Interventions
Yizhi Annao Granule treatment group:Yizhiannao Granule
Sponsors
The First Affiliated Hospital of Anhui University of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
45 Years to 80 Years
Inclusion criteria
Inclusion criteria: Consistent with DSM-V or NINDS-AIREN established may be the diagnosis of VaD and vascular cognitive impairment in patients; (1) Hachinski ischemic scale (HIS) score> 4; (2) MRI examination of acute stage of cerebral infarction, recovery period evidence; (3) study into the patient must be within six months of stroke; (4) MMSE baseline score between 11-26 points, in line with light to moderate; (5) weight between 45-90kg; (6) aged 45 to 80 years, men and women; (7) voluntary participation in this trial and signed informed consent; (8) have a certain degree of education, previously able to read simple articles and write simple sentences.
Exclusion criteria
Exclusion criteria: (1) primary dementia, early manifestations of memory impairment, progressive increase, accompanied by other cognitive impairment such as aphasia, loss, loss of consciousness, and the lack of relevant brain imaging of focal lesions; (2) there was no focal neurological signs except for cognitive impairment; (3) No autosomal dominant arterial disease (CADASIL) of hippocampal volume or medial temporal lobe atrophy, or cerebral hemorrhagic dementia and subcortical arteriosclerotic encephalopathy or subcortical infarct and leukoencephalopathy were detected by CT or MRI; (4) Hachinski ischemic scale (HIS) score=4; (5) Hamilton Depression Rating Scale (HAMD) score> 17 points, or depression patients, or patients with other psychiatric or mental disorders; (6) Other patients with secondary dementia, depressive dementia, psychomotor excitation, psychotic episodes, epilepsy, and patients with acute or poorly controlled disease are excluded from the income spectrum; (7) suffering from certain diseases that interfere with cognitive function assessment, including alcohol consumption, or drug abuse or other psychotropic substance abuse in the past five years; (8) with severe neurological deficits that can not complete the examination, such as hand hemiplegia, a variety of aphasia, audio-visual disorders; (9) in the past 30 days have been treated with similar drugs, such as taking related or antagonistic drugs, the efficacy of drugs is difficult to judge. With other research medication, psychotropic drugs, psychotropic side effects of drugs, oral anticoagulant and medication history of patients with blood circulation, short-acting diazepam application; (10) patients undergoing cardiac pacemaker surgery, coronary intervention and coronary artery bypass surgery, with intra-articular magnetic implants, who can not undergo magnetic resonance imaging; (11) of the test drug allergy; (12) to participate in other clinical drug trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alzheimer's disease assessment scale, ADAS-cog;Verbal Fluency Test;Trail Making Test;Stroop Color-word Test;Clock Drawing Test;HVLT-R;Symbol Digit Modalities Test;rs-fMRI;white matter structural integrity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mini-Mental Status Examination;activity of daily living;NIH Stroke Scale; | — |
Countries
China
Contacts
Public ContactDaojun Xie
The First Affiliated Hospital of Anhui University of traditional Chinese Medicine
Outcome results
None listed